Predicting, Diagnosing and Treating Synucleinopathies

Parkinson’s Disease and Lewy Body Dementia carry a high socioeconomic burden and there are currently no disease-modifying treatments. Existing symptomatic therapies focus on replacing neurotransmitters that are made by neurons that have mostly degenerated prior to clinical diagnosis, warranting a clear need to identify cases at a stage when they might benefit most from neuroprotective interventions, as well as improving symptomatic and developing disease modifying treatments.